Platform-Nanjing Immunophage Biomedical Co., Ltd

Medicinal Chemistry Platform
Antibody Platform
In Vivo and In Vitro Platform
Regulatory Affairs (RA) & Project Management (PM) Team
Clinical Medicine Team
Clinical Operation Team

Medicinal Chemistry Platform

• An end-to-end integrated platform spanning target validation to Preclinical Candidate (PCC) selection
• Lead compound discovery and optimization accelerated through AI-aided chemical design, integrated synthetic chemistry, analytical chemistry, and pharmacokinetics platforms
• Equipped with advanced analytical instruments including High-Performance Liquid Chromatography (HPLC), Liquid Chromatography-Mass Spectrometry (LC-MS), and Nuclear Magnetic Resonance (NMR) spectroscopy
Antibody Platform

• A highly efficient, well-established platform specialized in G protein-coupled receptor (GPCR)-targeting antibody drug discovery
• Generated high-affinity, high-selectivity GPCR antibodies with AI-aided prediction of antibody drugability, potent signal-blocking activity and multi-species cross-reactivity, facilitating seamless pharmacodynamic and toxicological evaluation
• Robust, scalable cell expression and purification platform for consistent production of high-quality therapeutic antibodies
In Vivo and In Vitro Platform

• Comprehensive in vitro platform supporting high-throughput screening of small molecules and antibodies, with specialized capabilities for GPCR antagonist potency and pharmacokinetic evaluation
• State-of-the-art Specific Pathogen-Free (SPF) animal facilities enabling rigorous early safety assessment, pharmacokinetic (PK), and pharmacodynamic (PD) studies
• Unique expertise in developing clinically translatable animal models, including orthotopic tumor models, spontaneous autoimmune disease models, and neurodegenerative disease models in both non-human primates and rodents
Regulatory Affairs (RA) & Project Management (PM) Team

Our integrated RA & PM team maintains close working relationships with regulatory authorities in China, the United States, Australia, and other global markets. We develop tailored regulatory strategies to accelerate IND approvals and ensure timely advancement of our entire pipeline.
Clinical Medicine Team

Our clinical medicine team works in close alignment with clinical practice, prioritizing patient safety and clinical value above all else. We specialize in designing innovative, evidence-based drug development strategies and collaborate closely with leading clinical researchers from the earliest stages of development to maximize the therapeutic potential of our candidates. By addressing critical unmet clinical needs and staying at the forefront of industry and research trends, we aim to deliver optimal therapies to patients worldwide.
Clinical Operation Team

Our clinical operations team brings extensive expertise in clinical project management, data management, biostatistics, pharmacovigilance, and clinical pharmacology. We possess in-depth knowledge of global clinical trial regulations and guidelines, ensuring the compliant, efficient, and high-quality execution of all our clinical development programs.

About
Pipeline
- IPG11406 IPG1094
- IPG7236 IPG0521
- IPG8294 IPG6620
- IPG0916
Publications
- Paper
- Patent
News
- Press Release
- Media Reports
Careers
- Join Us

Cpyright © 2025 Nanjing Immunophage Biomedical Co.,Ltd

All Rights Reserved. 苏ICP备2022026466号-1 苏公网安备 32011202000830号